Please login to the form below

Not currently logged in
Email:
Password:

King Pharmaceuticals

This page shows the latest King Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

FDA panel backs Pfizer and Teva abuse-resistant painkillers

The company secured rights to Troxyca ER (also known as ALO-02) when it acquired King Pharmaceuticals in 2010 for $3.6bn.

Latest news

  • Opioid analgesics

    The initial development of this immediate-release tamper-resistant formulation, formally known as Acurox, was under collaboration with Acura and King Pharmaceuticals. ... As part of the research programme initiated by King Pharmaceuticals (now Pfizer)

  • Burton Paul appointed to 1HQ’s health division

    Paul brings more than 15 years experience in managing projects and clients across a wide range of sectors including FMCG and pharmaceuticals. ... His work includes brand delivery for some of the biggest names in the sector, most notably: Adcock Ingram,

  • Lipitor losses affect Pfizer's Q2 sales

    Sales were aided by the purchase of King Pharmaceuticals, with Pfizer gaining an extra $357m in sales.

  • FDA approves Pfizer's pain drug

    Oxecta was originally developed by King Pharmaceuticals. Pfizer acquired the drug when it purchased King in late 2010.

  • Survival strategy

    Marketed products. The M&A strategy in 2010 was reflected in Pfizer's acquisition of King Pharmaceuticals for $3.6bn announced in October and Astellas' acquisition of OSI Pharmaceuticals for $4bn ... Nevertheless there were a few deals in 2010, such as

More from news
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....